Brian Peter Zambrowicz
Direktor/Vorstandsmitglied bei Texas A&M Institute for Genomic Medicine
Aktive Positionen von Brian Peter Zambrowicz
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Texas A&M Institute for Genomic Medicine
 Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Brian Peter Zambrowicz
Ehemalige bekannte Positionen von Brian Peter Zambrowicz
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.1995 | 24.02.2015 |
| Gründer | 07.07.1995 | 24.02.2015 | |
| NUEVOLUTION AB (PUBL) | Direktor/Vorstandsmitglied | - | - |
| Corporate Officer/Principal | - | - |
Ausbildung von Brian Peter Zambrowicz
| University of Wisconsin | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Dänemark | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Brian Peter Zambrowicz
- Erfahrung
